Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
WEST LAFAYETTE, Ind., May 01, 2018 -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at Deutsche Bank’s 43rd Annual Health Care Conference being held at the Intercontinental Hotel Boston on Tuesday, May 8th at 1:35 p.m. EDT.
A live audio webcast of the Company's presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte's website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company's website for 90 days following the conference.
Website Information
Endocyte routinely posts important information for investors on its website, www.endocyte.com, in the “Investors & News” section. Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the “Investors & News” section of Endocyte’s website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic in 2018, where it will be studied in osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.
Investor Contact:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
